Prostatype Genomics 관리

관리 기준 확인 1/4

Prostatype Genomics CEO는 Fredrik Rickman, Jan2017 에 임명되었습니다 의 임기는 7.83 년입니다. 는 € 162.99 가치에 해당하는 회사 주식의 0.018% 직접 소유합니다. 162.99. 경영진과 이사회의 평균 재임 기간은 각각 1.9 년과 4.1 년입니다.

주요 정보

Fredrik Rickman

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	7.8yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	1.9yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

CEO

Fredrik Rickman

7.8yrs

테뉴어

Mr. Fredrik Rickman (Previously Fredrik Rickman) has been Chief Executive Officer of Prostatype Genomics AB (publ) since 2017 and serves as its Managing Director. He has years of international life science...

리더십 팀

이름	위치	테뉴어	보상	소유권
Fredrik Rickman	CEO & MD	7.8yrs	데이터 없음	0.018% € 160.7
Anders Koch	Chief Financial Officer	1.1yrs	데이터 없음	데이터 없음
George Skinner	Vice President Commercial operations	no data	데이터 없음	데이터 없음
Emelie Berglund	Chief Technology Officer	2yrs	데이터 없음	0.0011% € 10.1
Nicklas Rosendal	Communications Director	3.2yrs	데이터 없음	데이터 없음
Joakim Soderin	Chief Auditor	2.4yrs	데이터 없음	데이터 없음
Gerald Andriole	Global Chief Medical Officer	1.5yrs	데이터 없음	데이터 없음
Steven Gaal	President US operations	1.8yrs	데이터 없음	데이터 없음
Katarina Sjöberg	QA & RA Manager	1.8yrs	데이터 없음	데이터 없음
Mats Bergström	Sales Director of EMEA	no data	데이터 없음	데이터 없음

1.9yrs

평균 재임 기간

경험이 풍부한 관리: PGO0 의 관리팀은 경험 (평균 재직 기간 1.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Anders Lundberg	Independent Chairman of the Board	7.8yrs	데이터 없음	데이터 없음
Mattias Prage	Independent Director	2.4yrs	데이터 없음	데이터 없음
Hakan Englund	Independent Director	5.8yrs	데이터 없음	0.85% € 7.8k
Michael Haggman	Independent Director	6.8yrs	데이터 없음	7.49% € 68.2k
Rolf Skoglund	Member of Advisory Board	no data	데이터 없음	데이터 없음
Jörgen Dahlström	Independent Director	less than a year	데이터 없음	0.010% € 91.8
Johan Waldhe	Director	less than a year	데이터 없음	데이터 없음

4.1yrs

평균 재임 기간

경험이 풍부한 이사회: PGO0 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Prostatype Genomics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Independent Director recently bought €72k worth of stock

Prostatype Genomics AB (Publ) Elects Johan Waldhe as New Member of the Board

Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors Prematurely

Prostatype Genomics Appoints Anders Koch as New CFO

Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company

Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer

Recent updates

Independent Director recently bought €72k worth of stock

Prostatype Genomics AB (publ) has completed a Composite Units Offering in the amount of SEK 39.535402 million.

First half 2024 earnings released: kr0.031 loss per share (vs kr0.37 loss in 1H 2023)

Prostatype Genomics AB (Publ) Elects Johan Waldhe as New Member of the Board

Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala

Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®

Prostatype Genomics AB (publ) to Report Fiscal Year 2024 Results on Feb 13, 2025

Full year 2023 earnings released

Prostatype Genomics AB (publ) Announces Long Term Follow Up Study At Akademiska University Hospital, Uppsala, to Be Presented At EAU-Meeting, May 2024: Indicates New Area of Use for Prostatype®

Prostatype Genomics AB (publ) Announces Henrik Nilsson to Leave the Board of Directors Prematurely

Prostatype Genomics Appoints Anders Koch as New CFO

Prostatype Genomics AB (Publ) Announces Updated Strategy and Implementation of Efficiency Programs in Prostatype Genomics

Prostatype Genomics Announces New Multi-Centre Study in Spain Shows Very Strong Interim Results for Prostatype(R)

Forecast to breakeven in 2025

Prostatype Genomics CFO Michael af Winklerfelt Leaving the Company

Forecast to breakeven in 2025

Second quarter 2023 earnings released

Prostatype Genomics AB (Publ) Provides Revenue Guidance for the Third Quarter of 2023

Now 22% undervalued after recent price drop

Prostatype Genomics AB Appoints Gerald Andriole as Chief Medical Officer

First quarter 2023 earnings released

Prostatype Genomics AB (Publ) Announces Executive Changes

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 17.787846 million.

Prostatype Genomics AB Appoints Professor Gerald Andriole as Chief Medical Officer

Full year 2022 earnings released: kr1.27 loss per share (vs kr1.11 loss in FY 2021)

Prostatype Genomics AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023

Prostatype Genomics AB (publ) to Report Q2, 2023 Results on Aug 17, 2023

Prostatype Genomics Appoints Steven Gaal as President

Prostatype Genomics AB (Publ) Provides Sales Guidance for the Year 2022

Prostatype Genomics Announces Management Changes

Prostatype Shows Strong Data in Asian Pilot Study

Second quarter 2022 earnings released

High number of new directors

Prostatype Genomics AB (Publ) Appoints Mattias Prage as Member of the Board

First quarter 2022 earnings released

Insufficient new directors

Prostatype Genomics AB (publ) to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

Third quarter 2021 earnings released

Prostatype Genomics AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.724583 million.

Second quarter 2021 earnings released: kr0.18 loss per share (vs kr0.42 loss in 2Q 2020)

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간